DRYS & CBLI continue north. a strong commitment by CEO: Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, “The pursuit of approval by the EMA and FDA and commercialization for entolimod as a medical radiation countermeasure remains our top priority.” http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12230538
Well positioned w/ powerful balance sheet, tiny debt and strong Cash on Hand ( per 10Q, fully funded until a year ahead ).
"At June 30, 2017 , we had cash, cash equivalents and short-term investments of $11.5 million in the aggregate. Management believes this capital will fund the Company's operations and cash requirements for at least 12 months beyond the filing date of this Quarterly Report on Form 10-Q".
makes if safer hold thru phase 3 & phase 2 catalysts.
Jarrod Wesson back in April 2017 wrote :
* "Investors should remark that the company owns two drugs in Phase 2 as well as the Entolimod-Biodefense that is in Phase 3"
* "the balance sheet looks very clean right now. The company showed in the last 10-k that it had about $15 million in total assets and only $3 million in total liabilities. It is also remarkable that the company has no long term debt, and 99% of its assets are short-term investments or cash on hand".
* "Cleveland BioLabs is very close to commercializing its new drug Entolimod and has other drugs in Phase 2".
in this case I think most would agree that $30m company could easily shift into high gear towards $300-$500m company relating this blockbaster potential drug.
News 
Market Data 
Discover 
